229 related articles for article (PubMed ID: 17518616)
21. Foamy virus vectors for gene transfer.
Trobridge GD
Expert Opin Biol Ther; 2009 Nov; 9(11):1427-36. PubMed ID: 19743892
[TBL] [Abstract][Full Text] [Related]
22. Foamy virus vector integration sites in normal human cells.
Trobridge GD; Miller DG; Jacobs MA; Allen JM; Kiem HP; Kaul R; Russell DW
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1498-503. PubMed ID: 16428288
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.
Bauer TR; Tuschong LM; Calvo KR; Shive HR; Burkholder TH; Karlsson EK; West RR; Russell DW; Hickstein DD
Mol Ther; 2013 May; 21(5):964-72. PubMed ID: 23531552
[TBL] [Abstract][Full Text] [Related]
24. Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis.
Biasco L; Rothe M; Schott JW; Schambach A
Hematol Oncol Clin North Am; 2017 Oct; 31(5):737-752. PubMed ID: 28895844
[TBL] [Abstract][Full Text] [Related]
25. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors.
Modlich U; Navarro S; Zychlinski D; Maetzig T; Knoess S; Brugman MH; Schambach A; Charrier S; Galy A; Thrasher AJ; Bueren J; Baum C
Mol Ther; 2009 Nov; 17(11):1919-28. PubMed ID: 19672245
[TBL] [Abstract][Full Text] [Related]
26. Lentiviral vector integration sites in human NOD/SCID repopulating cells.
Laufs S; Guenechea G; Gonzalez-Murillo A; Zsuzsanna Nagy K; Luz Lozano M; del Val C; Jonnakuty S; Hotz-Wagenblatt A; Jens Zeller W; Bueren JA; Fruehauf S
J Gene Med; 2006 Oct; 8(10):1197-207. PubMed ID: 16960916
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
[TBL] [Abstract][Full Text] [Related]
28. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.
Deichmann A; Hacein-Bey-Abina S; Schmidt M; Garrigue A; Brugman MH; Hu J; Glimm H; Gyapay G; Prum B; Fraser CC; Fischer N; Schwarzwaelder K; Siegler ML; de Ridder D; Pike-Overzet K; Howe SJ; Thrasher AJ; Wagemaker G; Abel U; Staal FJ; Delabesse E; Villeval JL; Aronow B; Hue C; Prinz C; Wissler M; Klanke C; Weissenbach J; Alexander I; Fischer A; von Kalle C; Cavazzana-Calvo M
J Clin Invest; 2007 Aug; 117(8):2225-32. PubMed ID: 17671652
[TBL] [Abstract][Full Text] [Related]
29. Retrovirus and lentivirus vector design and methods of cell conditioning.
Cooray S; Howe SJ; Thrasher AJ
Methods Enzymol; 2012; 507():29-57. PubMed ID: 22365768
[TBL] [Abstract][Full Text] [Related]
30. Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells.
Leurs C; Jansen M; Pollok KE; Heinkelein M; Schmidt M; Wissler M; Lindemann D; Von Kalle C; Rethwilm A; Williams DA; Hanenberg H
Hum Gene Ther; 2003 Apr; 14(6):509-19. PubMed ID: 12718762
[TBL] [Abstract][Full Text] [Related]
31. Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors.
Hu J; Renaud G; Gomes TJ; Ferris A; Hendrie PC; Donahue RE; Hughes SH; Wolfsberg TG; Russell DW; Dunbar CE
Mol Ther; 2008 Sep; 16(9):1617-23. PubMed ID: 18578011
[TBL] [Abstract][Full Text] [Related]
32. Foamy virus as a gene transfer vector to the central nervous system.
Caprariello AV; Miller RH; Selkirk SM
Gene Ther; 2009 Mar; 16(3):448-52. PubMed ID: 19052632
[TBL] [Abstract][Full Text] [Related]
33. Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity.
Suerth JD; Maetzig T; Brugman MH; Heinz N; Appelt JU; Kaufmann KB; Schmidt M; Grez M; Modlich U; Baum C; Schambach A
Mol Ther; 2012 May; 20(5):1022-32. PubMed ID: 22334016
[TBL] [Abstract][Full Text] [Related]
34. Malignant transformation of mature T cells after gammaretrovirus mediated transfer of nucleophosmin-anaplastic lymphoma kinase oncogene.
Kumar A
Indian J Pathol Microbiol; 2015; 58(3):301-6. PubMed ID: 26275250
[TBL] [Abstract][Full Text] [Related]
35. Historical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy.
Kohn DB
Hematol Oncol Clin North Am; 2017 Oct; 31(5):721-735. PubMed ID: 28895843
[TBL] [Abstract][Full Text] [Related]
36. Hot spots of retroviral integration in human CD34+ hematopoietic cells.
Cattoglio C; Facchini G; Sartori D; Antonelli A; Miccio A; Cassani B; Schmidt M; von Kalle C; Howe S; Thrasher AJ; Aiuti A; Ferrari G; Recchia A; Mavilio F
Blood; 2007 Sep; 110(6):1770-8. PubMed ID: 17507662
[TBL] [Abstract][Full Text] [Related]
37. Retroviral integration and human gene therapy.
Bushman FD
J Clin Invest; 2007 Aug; 117(8):2083-6. PubMed ID: 17671645
[TBL] [Abstract][Full Text] [Related]
38. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
Doi K; Takeuchi Y
Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
[TBL] [Abstract][Full Text] [Related]
39. Comparative clonal analysis of reconstitution kinetics after transplantation of hematopoietic stem cells gene marked with a lentiviral SIN or a γ-retroviral LTR vector.
Cornils K; Bartholomae CC; Thielecke L; Lange C; Arens A; Glauche I; Mock U; Riecken K; Gerdes S; von Kalle C; Schmidt M; Roeder I; Fehse B
Exp Hematol; 2013 Jan; 41(1):28-38.e3. PubMed ID: 22989760
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes.
Zhou S; Fatima S; Ma Z; Wang YD; Lu T; Janke LJ; Du Y; Sorrentino BP
Mol Ther; 2016 Jun; 24(6):1090-1099. PubMed ID: 26957223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
